Grace Therapeutics (GRCE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Grace Therapeutics (GRCE) is Moderate Underperform.

The composite score behind that read is -0.39, weighing +0.00 of bullish evidence against -0.39 bearish.

Grace Therapeutics last closed at $2.06, -0.48% on the session.

Against the IVW growth benchmark the position is -1.40% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

16 graded predictions for GRCE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Grace Therapeutics in the 22nd percentile on return on equity, where 100 is best.

Grace Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $43.54M.

StockMap tracks Grace Therapeutics as the 98th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Grace Therapeutics ranks 93rd of 128 in the group, against a group median of -0.24.